Intended Use

Rapid test for the qualitative determination of rheumatoid factor in serum by agglutination of latex particles on slide. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.

Summary

The term rheumatoid factor evolved from the observations of Waaler¹ and Rose², who noted that serum from a high proportion of patients with rheumatoid arthritis agglutinated sheep erythrocytes sensitized with specific rabbit antibodies. Rheumatoid factor is now defined as a group of closely related antibodies specific to antigenic determinants on the Fc fragments of human or animal immunoglobulin G. They commonly belong to the three major classes of immunoglobulins.^{3,4}

A variety of tests are now available for the determination of rheumatoid factor being agglutination of human gammaglobulin coated latex particles one of the most widely used.³⁻⁵ A positive latex test, indicating the existence of rheumatoid factor, may be decisive for the diagnosis of rheumatoid arthritis in patients with inflammatory arthritis.

Principle

The Sure-Vue® RF reagent is a suspension of polystyrene latex particles of uniform size coated with human gammaglobulin. Latex particles allow visual observation of the antigen-antibody reaction. If the reaction takes place, due to the presence of rheumatoid factor in the serum, the latex suspension changes its uniform appearance and a clear agglutination becomes evident. This change occurs because the rheumatoid factor present in the serum reacts with the IgG coated to the latex particles, starting the formation of a web between them.

When you mix the latex reagent with the serum, if the serum contains approximately more than 10 IU/mL of rheumatoid factor, a clear agglutination will appear.

Results are expressed in International Units per mL (IU/mL) based on the WHO International Reference Preparation of Rheumatoid Arthritis Serum.⁶

Equipment and Materials

Reagents

a) Latex reagent:

Suspension of human IgG coated polystyrene latex particles in a buffer.

Contains sodium azide 0.1%.

b) Positive control:

Diluted human serum containing more than 10 IU/mL of rheumatoid factor. Ready to use. Contains sodium azide 0.1%.

c) Negative control:

Diluted human serum containing less than 10 IU/mL of rheumatoid factor. Ready to use. Contains sodium azide 0.1%.

Available packaging

- Kit 50 tests, Cat. No. 23 038003.

Contains: 1 x 2.5 mL reagent, 1 x 1.0 mL positive control, 1 x 1.0 mL negative control and 9 disposable slides with 6 sections each.

Material required but not provided

- Normal saline (0.9% NaCl, only for semiquantitative test).
- Automatic pipettes.
- Disposable stirrers.
- Rotator.
- Timer.

Precautions

Sure-Vue® RF is intended for IN VITRO diagnostic use.

The reagents in this kit contain sodium azide as a preservative. Sodium azide has been reported to form lead or copper azide in laboratory plumbing which may explode on percussion. Flush drains with water thoroughly after disposing of fluids containing sodium azide.

Each donor unit used in the preparation of the controls of this kit was tested by an FDA approved method for the presence of HIV 1/2 and HCV antibodies as well as for hepatitis B surface antigen and found to be negative.

WARNING: POTENTIALLY BIOHAZARDOUS MATERIAL.

Because no test method can offer complete assurance that HIV 1/2, HCV, hepatitis B virus, or other infectious agents are absent, the controls of this kit and serum samples should be handled carefully following procedures recommended for biohazardous material.⁷

Storage and Stability

The reagents will remain stable through the expiration date shown on the label, if stored between 2-8°C. Do not freeze. The reagents can be damaged by improper handling, especially temperature extremes. Checking with the positive and negative controls provided will permit detection of reagents deterioration.

The reagents should not be used after the expiration date shown on the label.

The latex reagent, once shaken, must be uniform without visible clumping. When stored a slight sedimentation may occur and should be considered normal.

Do not use reagents if they become contaminated.

The reagent dropper dispenses drops of 50 μ L \pm 10%. The dropper must be held perpendicular to the slide surface and a single drop allowed to fall. Do not use another dropper without previously checking the volume of the drop.

Specimen Collection

Use fresh serum collected by centrifuging clotted blood. If the test cannot be performed on the same day, the serum may be stored between 2-8°C for no longer than 8 days after collection. For longer storage, store samples frozen (-20°C).

It is not necessary to inactivate the serum.

As in all serological tests, hemolytic, lipemic or turbid sera may cause incorrect results and should not be used.

Do not use plasma.

Quality Control

Control of the latex reagent:

- Before performing a set of determinations it is advisable to check the latex reagent with each of the controls, positive and negative, included in the kit.
- Both controls should be used following the steps outlined in the QUALITATIVE TEST.
- The reaction between the positive control and the reagent should show a clear agglutination, different from the uniform appearance of the negative control. If no agglutination takes place, the test should be repeated, and the kit discarded if there is no positive reaction.

It is required that external quality control be performed every 30 days, with new shipments or lot number changes between reagent kits.

If the expected control reactions are not observed, repeat the control tests as the first step in determining the root cause of the failure. If control failures are repeated please notify department lead.

Send to Reference Laboratory for testing if in-house method unavailable due to unexpected control reactions.

Procedure-Qualitative (Stepwise)

- Allow reagents and samples to reach room temperature (20-30°C).
- Gently shake the reagent vial to disperse and suspend the latex particles in the buffer solution. Vigorous shaking should be avoided.
- Place 50 µL of the serum onto one section of the disposable slide.
- Place one drop of reagent next to the drop of serum.
- Mix both drops with a stirrer covering the whole surface of the slide section.
- Gently rotate the slide for 2 minutes manually or on a rotary shaker set at 80-100 rpm.
- Look for the presence or absence of agglutination after the aforementioned period of time.

Reporting Result

The presence of agglutination indicates a content of rheumatoid factor in the serum equal to or greater than $10 \, \text{IU/mL}$.

The absence of agglutination indicates a content of rheumatoid factor in the serum of less than 10 IU/mL.

POSITIVE REACTIONS:

- 3+ Large clumping with clear background.
- 2+ Moderate clumping with fluid slightly opaque in background.
- 1+ Small clumping with opaque fluid in background.

NEGATIVE REACTIONS:

No visible clumping, uniform suspension.

Expected Values

Establishing «normal values» for rheumatoid factor is difficult since its presence has little diagnostic value if it is not accompanied by signs that suggest the existence of rheumatoid arthritis.

In at least 70-80% of patients with rheumatoid arthritis the existence of rheumatoid factor can be proved through significant titers. The higher titers are usually related with the most serious cases of rheumatoid arthritis. The remaining patients are considered seronegative having rheumatoid factor titers falling in the normal range or not detectable by conventional tests.

In approximately 3-5% of the normal population there can be found rheumatoid factor at low titers. This proportion increases with the age of the population being studied.^{3,4}

Limitations of the Procedure

- Reading of the results after more than 2 minutes may give false positive results.
- The strength of agglutination is not necessarily indicative of relative rheumatoid factor concentration.
- Since increased levels of rheumatoid factor may accompany certain acute immune responses such as infectious mononucleosis, certain diseases such as sarcoidosis, systemic lupus erythematosus and Sjögren's syndrome and may also be found in a considerable percentage of elderly individuals, the interpretation of the clinical significance of a positive test result must be made with caution. Less

commonly, a positive test may result in situations where chronic inflammatory disease is suspected, such as bacterial endocarditis, tuberculosis, leprosy, etc. ³⁻⁵

- Certain patients with rheumatoid arthritis may show negative results for rheumatoid factor

Performance Characteristics

Sure-Vue® RF was evaluated by comparison with a commercially available latex test (samples 1:6 diluted). A total of 192 serum samples from hospital patients were tested following the qualitative test. This study demonstrated a 91.7% agreement between the tests. The discrepant results were subsequently re-analyzed by means of a quantitative latex enhanced turbidimetric method being their titers between 10 and 30 IU/mL.

In a second study the Sure-Vue® RF was compared to another commercially available latex test (undiluted samples). A total of 223 serum samples were tested including random patients samples from a hospital and stored samples previously known to be positive for rheumatoid factor. This study demonstrated a 96.0% agreement between both tests. The discrepant sera exhibited borderline results. A panel of 10 positive serum samples was tested on three consecutive days using the semiquantitative test. The results of the study indicate that Sure-Vue® RF in-house reproducibility (within one dilution) was 100%.

References

- 1. Waaler, E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Path. Microbiol. Scand. 17: 172-188, 1940.
- 2. Rose, H.M., Ragan, C., Pearce, E. and Lipman, M.O. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc. Soc. Exp. Biol. & Med. 68: 1-6, 1948.
- 3. Mannik, M. Rheumatoid factors. In: Arthritis and Allied Conditions, 9th edition. Lea & Febiger, Philadelphia, 1979, p: 504-512.
- 4. Carson, D.A. Rheumatoid factor. In: Textbook of Rheumatology. W.B. Saunders Co., Philadelphia, 1985, p: 664-679.
- Singer, J.M. and Plotz, C.M. The Latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. II. Results in rheumatoid arthritis. Amer. J. Med. 21: 888-896, 1956.
- Anderson, S.G., Bentzon, M.W., Houba, V. and Krag, P. International reference preparation of rheumatoid arthritis serum. Bull. Wld Hlth Org. 42: 311-318, 1970.
- 7. Biosafety in Microbiological and Biomedical Laboratories. CDC/NIH manual, 5th Edition, 2007.

Effective date	
	Effective date for this procedure:
Author	
	Compiled by Fisher HealthCare
	Revised by: Ana Petru, MT (ASCP)

Designee Authorized for annual Review

See Annual Procedure manual Review Policy.

LIS REPORTING: Sure-Vue® RF

The following directions for LIS reporting of the rheumatoid factor screen should be followed with each patient run:

- 1. Create worksheet
 - a. worksheet name "HRFSC"
 - b. worksheet name "HQC" to enter <u>ONLY</u> Quality Control results (DO NOT CREATE FOR PATIENT ONLY)
- 2. Following testing; Process worksheet
- 3. Enter both control values for RF test via worksheet "HQC"
- 4. Enter patient results via worksheet "HRFSC"
- 5. Print and Close worksheet
- 6. Place worksheet in center workstation area in Special Chemistry.

FOLLOWING TESTING: STORE ALL SPECIMENS IN SEROLOGY RACK IN JEWET T100 REFRIGERATOR IN SPECIAL CHEMISTRY